Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study.

Cells - 31 Jan 2021

Kupczyk Piotr, Simiczyjew Aleksandra, Marczuk Jakub, Dratkiewicz Ewelina, Beberok Artur, Rok Jakub, Pieniazek Malgorzata, Biecek Przemyslaw, Nevozhay Dmitry, Slowikowski Bartosz, Chodaczek Grzegorz, Wrzesniok Dorota, Nowak Dorota, Donizy Piotr

Abstract excerpt

(1) Background: Poly(ADP-ribose) polymerase 1) (PARP1) is a pleiotropic enzyme involved in several cellular processes, e.g., DNA damage repair, regulation of mitosis, and immune response. Little is known about the role of PARP1 in melanoma development and progression. We aimed to investigate the prognostic significance of PARP1 expression in cutaneous melanoma through evaluation of mRNA and protein levels of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Poly (ADP-Ribose) Polymerase-1

Share to Prognosis

Share to Skin Neoplasms

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 33572647
DOI: 10.3390/cells10020286
PMCID: PMC7911865

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study.PMID 33572647Read ↗

PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to AchieveSemantic proximity Read ↗

PARP4 deficiency enhances sensitivity to ATM inhibitor by impairing DNA damage repair in melanomaSemantic proximity Read ↗

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?Semantic proximity Read ↗

Homologous Recombination Deficiency (HRD) in Cutaneous OncologySemantic proximity Read ↗

Polo-like kinase 1 (Plk1) in non-melanoma skin cancersSemantic proximity Read ↗

Inherited variation in the PARP1 gene and survival from melanoma.Semantic proximity Read ↗

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In VivoSemantic proximity Read ↗

Genetic variation in DNA repair pathway genes and melanoma risk.Semantic proximity Read ↗

A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.Semantic proximity Read ↗

Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of HeterozygositySemantic proximity Read ↗

Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.Semantic proximity Read ↗

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.